Burning mouth syndrome responsive to pramipexol

• Published in: Journal of headache and pain Vol. 9; no. 1; pp. 43 - 45
• Main Authors: Stuginski-Barbosa, J., Rodrigues, G. G. R., Bigal, M. E., Speciali, J. G.
• Format: Journal Article
• Language: English
• Published: Milan Springer Milan 01-02-2008; Springer; Springer Nature B.V
• Subjects: Aged; Benzothiazoles - administration & dosage; Biological and medical sciences; Brief Report; Burning Mouth Syndrome - drug therapy; Burning Mouth Syndrome - metabolism; Burning Mouth Syndrome - physiopathology; Burns; Corpus Striatum - drug effects; Corpus Striatum - metabolism; Corpus Striatum - physiopathology; Diseases of striated muscles. Neuromuscular diseases; Dopamine - metabolism; Dopamine Agonists - administration & dosage; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance - drug effects; Drug Resistance - physiology; Drug therapy; Female; Humans; Internal Medicine; Medical disorders; Medical sciences; Medicine; Medicine & Public Health; Mouth; Mouth Mucosa - drug effects; Mouth Mucosa - innervation; Mouth Mucosa - physiopathology; Neurology; Neurons; Pain Medicine; Parkinson Disease - complications; Parkinson Disease - drug therapy; Parkinson Disease - physiopathology; Pramipexole; Prospective Studies; Receptors, Dopamine D2 - agonists; Receptors, Dopamine D2 - metabolism; Restless Legs Syndrome - drug therapy; Restless Legs Syndrome - physiopathology; Substance Withdrawal Syndrome - physiopathology; Traumas. Diseases due to physical agents; Treatment Outcome; Burning mouth syndrome; Pramipexol; Orofacial pain; Burn; Nervous system diseases; Treatment; Stomatology; Central nervous system disease; Oral cavity disease; Neurological disorder; Cerebral disorder
• ISSN: 1129-2369; 1129-2377
• DOI: 10.1007/s10194-008-0003-4

Burning mouth syndrome (BMS) is characterized by burning discomfort or pain in otherwise normal oral mucosa. It is usually refractory. Treatment modalities are scarce. Herein we report one case of primary disabling BMS, previously refractory to multiple regimens, with complete and persistent improvement with pramipexol, a nonergot dopamine agonist which has high selectivity for dopaminergic D2 receptors. We discuss potential pathophysiological implications of our findings.